DiaMedica Therapeutics Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DiaMedica Therapeutics stock.
View analyst ratings for DiaMedica Therapeutics or view top-rated stocks.

Wall Street analysts have given DiaMedica Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DiaMedica Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for DiaMedica Therapeutics.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) posted its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.04.
View DiaMedica Therapeutics' earnings history.

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DMAC stock has increased by 115.8% and is now trading at $8.63.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued twelve-month price objectives for DiaMedica Therapeutics' stock. Their forecasts range from $14.00 to $38.00. On average, they anticipate DiaMedica Therapeutics' stock price to reach $23.83 in the next year. This suggests a possible upside of 176.2% from the stock's current price.
View analysts' price targets for DiaMedica Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to DiaMedica Therapeutics include Evolus (EOLS), Summit Therapeutics (SMMT), Albireo Pharma (ALBO), Applied Therapeutics (APLT), ZIOPHARM Oncology (ZIOP), Clovis Oncology (CLVS), Annovis Bio (ANVS), Adagene (ADAG), Bolt Biotherapeutics (BOLT), Inventiva (IVA), Catalyst Pharmaceuticals (CPRX), Selecta Biosciences (SELB), Akebia Therapeutics (AKBA), Atossa Therapeutics (ATOS) and Magenta Therapeutics (MGTA).
View all of DMAC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

DiaMedica Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Corriente Advisors LLC (4.63%), Point72 Asset Management L.P. (2.94%), Granite Point Capital Management L.P. (0.98%), Renaissance Technologies LLC (0.81%), Geode Capital Management LLC (0.68%) and EAM Investors LLC (0.58%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen.
View institutional ownership trends for DiaMedica Therapeutics.

DMAC stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Point72 Asset Management L.P., Northern Trust Corp, Bank of New York Mellon Corp, and EAM Investors LLC.
View insider buying and selling activity for DiaMedica Therapeutics or view top insider-selling stocks.

DMAC stock was bought by a variety of institutional investors in the last quarter, including Corriente Advisors LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, Millennium Management LLC, Geode Capital Management LLC, Bank of Montreal Can, Citadel Advisors LLC, and Citadel Advisors LLC. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Randall Michael Giuffre, Richard D Pilnik, and Scott Kellen.
View insider buying and selling activity for DiaMedica Therapeutics or or view top insider-buying stocks.

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DMAC stock can currently be purchased for approximately $8.63.

DiaMedica Therapeutics has a market capitalization of $162.12 million and generates $500,000.00 in revenue each year. The company earns $-12,290,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

DiaMedica Therapeutics employs 10 workers across the globe.

The official website for DiaMedica Therapeutics is www.diamedica.com.

DiaMedica Therapeutics is headquartered at 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447.

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]